ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 49.6 | 33.9 | 49.5 |
| Other income | 0.2 | 0.0 | 0.0 |
| Total income | 49.8 | 33.9 | 49.5 |
| Profit before exceptional items & tax | -1.3 | -6.3 | -3.8 |
| Profit before tax | -1.3 | -6.3 | -3.8 |
| Net profit | -1.7 | -4.8 | -2.2 |
| Operating margin | -2.6% | -18.6% | -7.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +0.20% |
|---|
BSE results filing, NSE: SSORGS. Figures extracted from the filing.
Oxygenta Pharmaceutical Ltd: key numbers
- Share price
- ₹48.60
- Market cap
- ₹179.7 Cr
- Revenue (annual)
- ₹113.0 Cr
- Net profit (annual)
- ₹-17.57 Cr
- P/E (TTM)
- -15.8×Sector 43.8×
- Promoter holding
- 56.54%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Oxygenta Pharmaceutical Ltd
All →Oxygenta Pharmaceutical Q2 FY27 Results: Net Loss of ₹2.7 Cr, Loss Narrows
Oxygenta Pharmaceutical's board approved unaudited results for the quarter and half year ended 30 September 2026, showing quarterly revenue of Rs 3,351.41 lakhs and a net loss of Rs 273.53 lakhs. The filing includes the full SEBI results statement, balance sheet, cash flow and limited review report.
- Key figure
- Net loss ₹2.7 Cr
Oxygenta Pharmaceutical Board Meeting Date
Oxygenta Pharmaceutical Limited has scheduled a board meeting for November 10, 2026. The board will primarily consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.
Oxygenta Pharmaceutical Other Announcement
The company filed its quarterly shareholding pattern as mandated under Regulation 31(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Oxygenta Pharmaceutical Acquisition Worth ₹6.75 Cr
Oxygenta Pharmaceutical acquired land in Telangana from TGIIC for Rs. 6.75 Crore. The purchase supports business expansion and long-term strategic infrastructure needs.
- Value
- ₹6.75 Cr
Oxygenta Pharmaceutical Annual General Meeting
Oxygenta Pharmaceutical Limited conducted its 33rd Annual General Meeting on August 21, 2026, via video conferencing to discuss and adopt various corporate business resolutions.
Oxygenta Pharmaceutical Annual Report
Oxygenta Pharmaceutical has submitted its 33rd Annual Report for FY 2025-26, including the notice for the upcoming Annual General Meeting scheduled for August 21, 2026.